Eli Lilly and Company Reports $303M In Q3 2026 Special Charges, Bringing 9-Month Total To $1.3B, Primarily Driven By Intangible Asset Impairment, Acquisition Costs And Litigation
Note 5: Asset Impairment, Restructuring, and Other Special ChargesAsset impairment, restructuring, and other special charges recognized during the three and nine months ended September 30, 2026 were $303 million and
Eli Lilly took large charges against profits from past deals and legal costs. When a company writes down big losses like this, watch whether the core business is still growing steadily.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.